Compare CENT & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CENT | IDYA |
|---|---|---|
| Founded | 1955 | 2015 |
| Country | United States | United States |
| Employees | 6000 | N/A |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.6B |
| IPO Year | N/A | 2019 |
| Metric | CENT | IDYA |
|---|---|---|
| Price | $43.98 | $37.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 16 |
| Target Price | $50.00 | ★ $52.86 |
| AVG Volume (30 Days) | 77.5K | ★ 1.6M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.90 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $218,710,000.00 |
| Revenue This Year | $1.60 | N/A |
| Revenue Next Year | $2.04 | $201.05 |
| P/E Ratio | $15.73 | ★ N/A |
| Revenue Growth | N/A | ★ 3024.43 |
| 52 Week Low | $28.77 | $21.33 |
| 52 Week High | $45.78 | $39.28 |
| Indicator | CENT | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 62.16 | 71.16 |
| Support Level | $35.55 | $29.51 |
| Resistance Level | $45.78 | $38.17 |
| Average True Range (ATR) | 1.23 | 1.68 |
| MACD | -0.03 | 0.55 |
| Stochastic Oscillator | 57.04 | 93.98 |
Central Garden & Pet Co offers solutions that support healthier pets, greener lawns, and thriving gardens. Its products include dog and cat treats, chews, toys, beds, containment, grooming supplies, aquatics, small animal and bird supplies, equine and livestock products, insect control solutions, grass seed, wild bird feed, fertilizers, pest controls, live plants, and packet seeds, sold under brands such as Aqueon, Nylabone, Kaytee, Farnam, Pennington, Ferry Morse, Amdro, and Sevin. The company operates through two segments, Pet and Garden, and sells through retailers, independent stores, eCommerce channels, and professional markets. It has sales and distribution operations mainly across the United States, with additional facilities in Canada and Mexico.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.